Expert Review of Clinical Pharmacology

Papers
(The TQCC of Expert Review of Clinical Pharmacology is 7. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)
ArticleCitations
Sodium-glucose cotransporter 2 inhibitors in frail, older people with type 2 diabetes and heart failure: do we have enough evidence to confidently support the use?190
Strategies for lowering lipoprotein(a): a spotlight on novel pharmacological treatments173
Personalizing tamoxifen therapy in adjuvant therapy: a brief summary of the ongoing discussion54
Pharmacological and clinical profile of ravulizumab 100 mg/mL formulation for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome43
Why is diagnosis, investigation, and improved management of kidney stone disease important? Non-pharmacological and pharmacological treatments for nephrolithiasis41
Reducing the risk of death – a possible outcome in COPD patients39
Renin angiotensin aldosterone inhibitors in the treatment of proteinuria in children with congenital anomalies of the kidney and urinary tract: more evidence needed36
Risk of new onset diabetes mellitus with pitavastatin as compared to atorvastatin and rosuvastatin: a systematic review and meta-analysis33
Therapeutic drug monitoring of antiretroviral therapy: current progresses and future directions30
Effects of the augmentation with quetiapine or olanzapine on the metabolism of duloxetine: a retrospective analysis30
Prostate cancer and novel pharmacological treatment options–what’s new for 2022?30
JAK inhibitors in dermatology: the road travelled and path ahead, a narrative review29
Clinical pharmacology of antiplatelet drugs29
What is the potential for abuse of lisdexamfetamine in adults? A preclinical and clinical literature review and expert opinion28
Brimonidine tartrate ophthalmic solution 0.025% for redness relief: an overview of safety and efficacy27
The pharmacotherapeutics of sarcoidosis27
Role of tenecteplase in ischemic stroke after 4.5 hours: an evaluation of the TRACE-III trial26
Fetal safety of medications used in treating infertility26
Broadening access to tenofovir alafenamide for the treatment and prevention of HIV-1 infection25
Amylin analogs for the treatment of obesity without diabetes: present and future25
Clinical efficacy and safety of topical difamilast in the treatment of patients with atopic dermatitis: a systematic review and meta-analysis of randomized controlled trials24
Dostarlimab for the treatment of advanced endometrial cancer23
Hugan tablets for the treatment of RUCAM based drug-induced liver injury: a propensity score matching analysis using a nationwide database21
Cannabidiol drug interaction considerations for prescribers and pharmacists20
Fixed-dose combination of rosuvastatin and ezetimibe: treating hypercholesteremia according to cardiovascular risk19
Nicotine e-cigarettes for smoking cessation: a clinical pharmacology perspective19
The thiazide-like diuretic chlorthalidone as an alternative evidence-based therapy for resistant hypertension in patients with stage 4 chronic kidney disease19
Reply to: The risk for genito-urinary infections with sodium-glucose cotransporter-2 inhibitors: duration rather than dose matter?18
Complications related to oral corticosteroid use in asthma patients: a retrospective cohort study18
Voclosporin: a novel calcineurin inhibitor for the treatment of lupus nephritis18
Pharmacogenetics-based population pharmacokinetic analysis for dose optimization of ritonavir-boosted atazanavir in Thai adult HIV-infected patients18
Recent pharmacological approaches for the treatment of renal cell carcinoma17
OPTIMA-ID: development and validation of a medicine optimization tool for older adults with intellectual disability17
Pharmacological strategies for the management of the antisocial personality disorder17
Nirmatrelvir/Ritonavir and molnupiravir: an update on COVID-19 antivirals in the Omicron era16
Drug-drug interactions associated with FLT3 inhibitors for acute myeloblastic leukemia: current landscape16
Association between sodium-glucose cotransporter 2 inhibitors and eye disorders: a systematic review and meta-analysis16
Hydroxyurea in the sickle cell disease modern era16
Effect of laparoscopic sleeve gastrectomy on drug pharmacokinetics15
Population pharmacokinetic modeling and exposure-response analysis of anrikefon: insights and implications in clinical analgesia15
Methenamine Hippurate in UTI management: a reemerging pharmacological strategy14
Pediatric attention deficit hyperactivity disorder (ADHD): 2022 updates on pharmacological management14
Current status and prospects of IL-6–targeting therapy14
Exposure–response modeling of the effect of glasdegib on cardiac repolarization in patients with cancer14
Clinical pharmacology of SGLT-2 inhibitors in heart failure14
A profile of azetukalner for the treatment of epilepsy: from pharmacology to potential for therapy14
Melflufen for the treatment of multiple myeloma14
Pharmacogenomics – a minor rather than major force in clinical medicine13
Revisiting the association between sodium-glucose cotransporter-2 inhibitors and the risk of neoplasm in patients with type 2 diabetes: new insights from an updated systematic review and meta-analysis13
The nocebo phenomenon in the COVID-19 pandemic: a nocebodemic effect13
A systematic review and meta-analysis of users versus non-users: unveiling the influence of proton pump inhibitors on capecitabine efficacy in colorectal cancer13
A narrative review of non-racemic amisulpride (SEP-4199) for treatment of depressive symptoms in bipolar disorder and LB-102 for treatment of schizophrenia13
Methotrexate polyglutamates13
Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF)13
Sodium zirconium cyclosilicate for the management of chronic hyperkalemia in kidney disease, a novel agent13
Antimicrobial safety considerations in critically ill patients: part II: focused on anti-microbial toxicities13
Designer benzodiazepines: an update13
Risk factors for a broken heart: understanding drug-induced causes for Takotsubo syndrome and pharmacological treatment options12
FLOT vs CROSS in localized esophageal adenocarcinoma: what is the current best strategy?12
Prevention of colistin induced nephrotoxicity: a review of preclinical and clinical data12
Real-world clinical effectiveness of once-weekly semaglutide in patients with type 2 diabetes: a systematic literature review12
Efficacy and safety of tislelizumab for malignant solid tumor: a systematic review and meta-analysis of phase III randomized trials12
Phosphatidylinositol 3 kinase inhibitor-related pneumonitis: a systematic review and meta-analysis12
Revolutionizing diabetes care: unveiling tirzepatide’s potential in glycemic control and beyond11
Encouraging appropriate use of proton pump inhibitors: existing initiatives and proposals for the future11
Interstitial lung disease associated with anti-HER2 anti-body drug conjugates: results from clinical trials and the WHO's pharmacovigilance database11
An observational study of safety and clinical outcome measures across patient groups in the United Kingdom Medical Cannabis Registry11
Efficacy and safety of dupilumab in chronic rhinosinusitis with nasal polyps: a systematic review and meta-analysis11
Optimization of secukinumab dose regimens in patients with moderate-to-severe plaque psoriasis via exposure-response modeling10
Gender differences in new hypoglycemic drug effects on renal outcomes: a systematic review10
Clinical pharmacology of siRNA therapeutics: current status and future prospects10
Biomarker discovery in acetaminophen hepatotoxicity: leveraging single-cell transcriptomics and mechanistic insight10
Is therapeutic drug monitoring a dancing partner for TNF-α inhibitors in real-world practice? Answers from an updated systematic review and meta-analysis10
Genito-urinary infectious adverse events related to sodium glucose cotransporter-2 inhibitors: a network meta-analysis and meta-regression10
Pharmacological and safety profile of a prolonged-release lanreotide formulation in acromegaly10
Immunotherapy of High Risk Non-Muscle Invasive Bladder Cancer10
Pharmacokinetic interaction of quetiapine and lamotrigine – victim and perpetrator?10
Signal mining study of severe cutaneous adverse events of valaciclovir or acyclovir based on the FAERS database10
TYK2 as a novel therapeutic target in psoriasis10
Clinical outcomes of oral anticoagulant discontinuation in atrial fibrillation: a systematic review and meta-analysis9
Inhaler technique in asthma and COPD: challenges and unmet knowledge that can contribute to suboptimal use in real life9
Adverse clinical outcomes associated with drug-related hospitalizations in people with dementia9
Pharmacological treatment for transforming growth factor beta induced corneal dystrophies: what is the way forward?9
Availability and evaluation of medication management resources for carers of people with dementia: a scoping review with an environmental scan9
Dasiglucagon for treating severe hypoglycemia in patients with diabetes9
Opioid use disorder in pediatric populations: considerations for perioperative pain management and precision opioid analgesia9
The future of pharmacology education: The Veterinary Educators in Pharmacology Special Interest Group (VEPSIG)9
Antimicrobial safety considerations in critically ill patients: part I: focused on acute kidney injury9
Recent advances in the pharmacological management of sepsis-associated acute kidney injury9
Reliance is key to effective access and oversight of medical products in case of public health emergencies8
The pharmacotherapeutic options in patients with catecholamine-resistant vasodilatory shock8
Comparing the renal outcomes in patients with atrial fibrillation receiving different oral anticoagulants8
Clozapine for treatment refractory catatonia in individuals with autism spectrum disorder: a retrospective chart review study8
Statin-related neurocognitive disorder: a real-world pharmacovigilance study based on the FDA adverse event reporting system8
Practical challenges and considerations in adopting biosimilars in oncology clinical practice within a large healthcare system8
Blinding and expectancy confounds in psychedelic randomized controlled trials8
Advances in pharmacokinetic-pharmacodynamic modelling for pediatric drug development: extrapolations and exposure-response analyses8
Keeping up with venetoclax for leukemic malignancies: key findings, optimal regimens, and clinical considerations8
Profile of estetrol, a promising native estrogen for oral contraception and the relief of climacteric symptoms of menopause8
Intravitreal immunotherapy in non-infectious uveitis: an update8
Current understanding of the etiology of cyclic vomiting syndrome and therapeutic strategies in its management8
Effects of single-nucleotide polymorphism on the pharmacokinetics and pharmacodynamics of metformin7
Detrimental impact of gastric acid suppressants on vascular endothelial growth factor receptor tyrosine kinase inhibitors efficacy: evidence from a systematic review and meta-analysis7
Epoprostenol for the treatment of pulmonary arterial hypertension7
The impact of body composition on treatment in ovarian cancer: a current insight7
Implementing pharmacogenetics in clinical trials: considerations about current methodological, ethical, and regulatory challenges7
The changes of IgE levels in type 2 inflammatory diseases after treatment of dupilumab: a systematic review and meta-analysis7
Impact of SGLT2 inhibitors on the kidney in people with type 2 diabetes and severely increased albuminuria7
Perspectives on deprescribing in older people with type 2 diabetes and/or cardiovascular conditions: challenges from healthcare provider, patient and caregiver perspective, and interventions to suppor7
Novel and emerging treatment strategies for lupus nephritis7
Optimizing outcomes and managing adverse events in locally advanced or metastatic urothelial cancer: a clinical pharmacology perspective7
Biosimilar development and review process in the BRICS-TM countries: Proposal for a standardized model to improve regulatory performance7
The impact of pregnancy-related hormonal and physiological changes on antiseizure medications: expert perspective7
Extending the ambit of SGLT2 inhibitors beyond diabetes: a review of clinical and preclinical studies on non-diabetic kidney disease7
Considerations when prescribing opioid agonist therapies for people living with HIV7
Intraperitoneal therapy for gastric cancer peritoneal carcinomatosis7
131-I-metaiodobenzylguanidine and chemotherapy for advanced neuroblastoma7
Quantitative effects of sodium-glucose cotransporter-2 inhibitors on liver functions in patients with nonalcoholic fatty liver disease7
Treatment and prevention of influenza in geriatric patients7
Next-generation sequencing in pharmacogenomics – fit for clinical decision support?7
0.18654799461365